Nebivolol
Beta Blocking Agents, Selective
Sold as BYSTOLIC
- Drug class
- Beta Blocking Agents, Selective
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 63
- FDA reports (12 mo)
- 1,666
Overview
Plain-language summary, compiled from the cited regulatory records
Nebivolol is a selective beta-adrenergic blocking agent [1]. It is approved for the treatment of hypertension, which is high blood pressure [1]. By lowering blood pressure, nebivolol can help reduce the risk of cardiovascular events, such as strokes and heart attacks [1].
Nebivolol may be used as a standalone treatment or in combination with other medications to manage hypertension [1].
In the past 12 months, there have been 1666 adverse event reports associated with nebivolol [2]. The most frequently reported adverse events include diarrhea, fatigue, nausea, and instances of off-label use or the drug being perceived as ineffective [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 45 | May 29, 2026 |
| CA Canada | Health Canada | 13 | January 28, 2026 |
| US United States | FDA | 5 | June 3, 2025 |
GBUnited Kingdom· MHRA
45 products
Uses
Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients of >70 years.
How to take
CACanada· Health Canada
13 products
Uses
BYSTOLIC® (nebivolol tablets) is indicated for: The treatment of mild to moderate essential hypertension. BYSTOLIC may be used alone or concomitantly with thiazide diuretics or angiotensin converting enzyme (ACE) inhibitors. 2 Recommended Dose and Dosage Adjustment and 14 CLINICAL TRIALS.
BYSTOLIC is not recommended for the emergency treatment of hypertensive crises. 1 Pediatrics The safety and efficacy of BYSTOLIC in pediatric patients have not been established and therefore use in children is not recommended. 2 Geriatrics No dosage adjustment is required in geriatric patients.
Of the total number of patients receiving BYSTOLIC in clinical studies, 436 (18%) were 65 years of age or older. No differences in efficacy or safety of BYSTOLIC were observed between older and younger patients. 3 Pharmacokinetics.
USUnited States· FDA
5 products
Uses
1 INDICATIONS AND USAGE Nebivolol is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. 1 ) ]. Nebivolol may be used alone or in combination with other antihypertensive agents [ see Drug Interactions ( 7 )].
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs.
There are no controlled trials demonstrating risk reduction with nebivolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.
Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Drug interactions
Known interactions involving Nebivolol. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 407. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL204160909 · revised July 18, 2025
- [2]Health Canada (DPD) · 02398990 · revised March 22, 2025
- [3]FDA DailyMed · 04a64dad-6922-47… · revised October 31, 2024 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.